Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CA12 | O43570 | 1/20 | 0.73 |
| ▸ | CA2 | P00918 | 1/20 | 0.73 |
| ▸ | CA3 | P07451 | 1/20 | 0.73 |
| ▸ | CA4 | P22748 | 1/20 | 0.73 |
| ▸ | CA6 | P23280 | 1/20 | 0.73 |
| ▸ | CA5A | P35218 | 1/20 | 0.73 |
| ▸ | CA7 | P43166 | 1/20 | 0.73 |
| ▸ | CA9 | Q16790 | 1/20 | 0.73 |
| ▸ | CA14 | Q9ULX7 | 1/20 | 0.73 |
| ▸ | CA5B | Q9Y2D0 | 1/20 | 0.73 |
| ▸ | DNM1 | Q05193 | 4/20 | 0.43 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.37 |
| ▸ | TSHR | P16473 | 2/20 | 0.37 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.37 |
| ▸ | MEN1 | O00255 | 2/20 | 0.36 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.36 |
| ▸ | TNNI3 | P19429 | 1/20 | 0.36 |
| ▸ | TNNT2 | P45379 | 1/20 | 0.36 |
| ▸ | TNNC1 | P63316 | 1/20 | 0.36 |
| ▸ | SIGMAR1 | Q99720 | 2/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12929089 | 1.00 | CA12 (0.73) | CA12CA2CA3CA4CA6 | |
| SCHEMBL16323098 | 1.00 | CA12 (0.73) | CA12CA2CA3CA4CA6 | |
| SCHEMBL29580954 | 0.89 | CA12 (0.53) | CA12CA2CA3CA4CA6 | |
| SCHEMBL5715864 | 0.89 | CA12 (0.53) | CA12CA2CA3CA4CA6 | |
| SCHEMBL29580952 | 0.89 | CA12 (0.53) | CA12CA2CA3CA4CA6 | |
| SCHEMBL14902390 | 0.89 | CA12 (0.58) | CA12CA2CA3CA4CA6 | |
| SCHEMBL129815 | 0.86 | — | — | |
| SCHEMBL10456533 | 0.86 | CA12 (1.00) | CA12CA2CA3CA4CA6 | |
| SCHEMBL36759 | 0.86 | CA12 (1.00) | CA12CA2CA3CA4CA6 | |
| SCHEMBL21631277 | 0.86 | CA12 (1.00) | CA12CA2CA3CA4CA6 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 64 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2023183887-A2 | COMPOSITIONS FOR AND METHODS OF MODULATING RNA STABILITY | DUKE UNIVERSITY (US) | 2023-09-28 | — | — | WO | disclosed |
| US-11680130-B2 | Composition | HUNTSMAN PETROCHEMICAL LLC (US) | 2023-06-20 | — | — | US | disclosed |
| EP-4180423-A1 | NOVEL TNF ACTIVITY INHIBITOR COMPOUND, AND PHARMACEUTICALLY ACCEPTABLE SALT THEREOF | ILAb Co., Ltd. (KR) | 2023-05-17 | — | — | EP | disclosed |
| EP-4116302-A1 | COMPOUND AND PREPARATION METHOD THEREOF AND APPLICATION THEREOF IN PREPARATION OF THERAPEUTIC ANTI-CANCER DRUG | Tianjin Jikun Medical Technology Co., Ltd. (CN) | 2023-01-11 | — | — | EP | disclosed |
| US-20210347932-A1 | Composition | HUNTSMAN PETROCHEMICAL LLC | 2021-11-11 | — | — | US | disclosed |
| EP-3530663-B1 | PROCESS FOR PREPARING GEM-DIFLUORINATED C-GLYCOSIDE COMPOUNDS | SUNSHINE BIOPHARMA INC (CA) | 2021-08-11 | — | — | EP | disclosed |
| WO-2021127044-A1 | COMBINATIONS | RECURIUM IP HOLDINGS, LLC (US) | 2021-06-24 | — | — | WO | disclosed |
| WO-2020132483-A1 | RIFAMYCIN ANALOGS AND ANTIBODY-DRUG CONJUGATES THEREOF | REGENERON PHARMACEUTICALS, INC. (US) | 2020-06-25 | — | — | WO | disclosed |
| EP-3530663-A1 | PROCESS FOR PREPARING GEM-DIFLUORINATED C-GLYCOSIDE COMPOUNDS | Advanomics Corp. (CA) | 2019-08-28 | — | — | EP | disclosed |
| EP-3330273-B1 | NOVEL METHOD FOR PREPARING AMINOSILANE-BASED COMPOUND | LG CHEMICAL LTD (KR) | 2019-06-19 | — | — | EP | disclosed |
| US-7879808-B2 | potent activity against resistant pneumococci; for treating domestic fowl | MEIJI SEIKA KAISHA, LTD. (JP) | 2011-02-01 | — | — | US | disclosed |
| EP-2099761-B1 | ANTIBACTERIAL QUINOLINE DERIVATIVES | JANSSEN PHARMACEUTICA NV (BE) | 2010-10-27 | — | — | EP | disclosed |
| US-20100210570-A1 | LINCOMYCIN DERIVATIVES AND ANTIMICROBIAL AGENTS COMPRISING THE SAME AS ACTIVE INGREDIENT | MEIJI SEIKA KAISHA LTD. (JP) | 2010-08-19 | — | — | US | disclosed |
| US-20090005321-A1 | Phenylazetidinone Derivatives | MICROBIA, INC. (US) | 2009-01-01 | — | — | US | disclosed |
| US-7384952-B2 | Pyrazolopyrimidine compound and a process for preparing the same | MITSUBISHI TANABE PHARMA CORPORATION (JP) | 2008-06-10 | — | — | US | disclosed |
| US-20080132500-A1 | Antibiotic compounds | MERCK SHARP & DOHME CORP. | 2008-06-05 | — | — | US | disclosed |
| WO-2008041053-A2 | INHIBITORS OF VEGF RECEPTOR AND HGF RECEPTOR SIGNALING | METHYLGENE, INC. (CA) | 2008-04-10 | — | — | WO | disclosed |
| EP-1857459-A2 | Pyrazolopyrimidine compound and a process for preparing the same | TANABE SEIYAKU CO., LTD. (JP) | 2007-11-21 | — | — | EP | disclosed |
| US-7169835-B2 | Stabilizer mixture | CIBA SPECIALTY CHEMICALS CORPORATION (US) | 2007-01-30 | — | — | US | disclosed |
| US-5266283-A | Oxygen sorption and desorption | BEND RESEARCH, INC. (US) | 1993-11-30 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100210570-A1 | LINCOMYCIN DERIVATIVES AND ANTIMICROBIAL AGENTS COMPRISING THE SAME AS ACTIVE INGREDIENT | LAS1L, LCLAT1, LYPLA1 | CA12 4449/4885CA2 4260/4885CA3 4757/4885 |
| US-20090005321-A1 | Phenylazetidinone Derivatives | TYR, AAAS, FANCD2 | CA12 4856/4885CA2 4388/4885CA3 4882/4885 |
| US-20080132500-A1 | Antibiotic compounds | NRDC, MRPL21, PEPD | CA12 4680/4885CA2 4584/4885CA3 4783/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.